トップページ > 研究組織一覧 > 分野・独立ユニットグループ > 新領域創成プロジェクトグループ > 希少がん研究分野 > 研究プロジェクト > 希少がん研究の基盤構築 > PDC(Patient-derived Cell)・PDX(Patient-derived Xenograft)の樹立 更新

PDC(Patient-derived Cell)・PDX(Patient-derived Xenograft)の樹立 更新

希少がん研究には、「症例数が少なく臨床検体が得難い」という特有の問題が存在します。臨床検体が得難いことに起因して、希少がん研究では研究に必要な基本的なツール(研究基盤)の開発が遅れています。希少がん研究分野は、希少がんの研究に必要な研究基盤の開発を行います。

PDC (Patient Derived Cell)とPDX(Patient-Derived Xenograft)の樹立

PDC (Patient-Derived Cells)やPDX(Patient-Derived Xenograft)はがん研究に必須のモデルとして使われてきました。たとえば、新しく発見した遺伝子異常の機能的な意義や、新しい薬の薬効評価などにおいて、PDCやPDXは使われています。しかしながら、希少がんではPDCやPDXは一般に入手がきわめて困難です。たとえば、肉腫を例に挙げると、公的な細胞バンクやバイオバンクに保管されているPDCやPDXはごく一部の肉腫にすぎません。また、細胞バンクに保管されている従来のPDCには、臨床情報が付随していない、遺伝的背景の情報がない、現在の診断基準とは異なる基準で診断名がついている、などの問題があります。なにかの研究をしようと思ったときにすぐに立ちはだかるのが、適切なPDCやPDXがない、という問題です。同様のことは肉腫以外のほとんどの希少がんについてあてはまります。「疾患として定義されてから何十年も経つにもかかわらず細胞株が一つもない」というのが、希少がんのよくある状況です。こういったことが原因となって、治療法の開発が進まないのです。

希少がん研究分野は、腫瘍組織からPDCやPDXの樹立を行っています。樹立されたPDCやPDXの分子背景の解析を行い、分子標的薬の標的となる遺伝子の異常を同定したり、希少がんに適応拡大可能な抗がんを探索したりしています。また、効率よく細胞株を樹立する方法を確立しています。樹立した細胞株は論文として発表し研究者に提供し、企業との共同研究に活用しています。

腫瘍組織

図 手術検体から細胞株、ゼノグラフトを作成する流れ。新しい三次元培養法を構築中です。

希少がんのPDCやPDXにご興味のある方はご一報ください。

文献

Kondo T. Current status and perspectives of patient-derived rare cancer models. Hum Cell. 2020 Jun 14. doi: 10.1007/s13577-020-00391-1. Epub ahead of print. PMID: 32537685. [PubMed](外部リンク)

  • 培養細胞の誕生と成長の記録
  • ゼノグラフト

提供可能な肉腫細胞株

2021.07.01更新

# Cancer type ID Original tumor type Comments(histology, fusion gene, ets) Ref
1 Leiomyosarcoma NCC-LMS1-C1 PDC These cell lines were established from tumors of LMS of bone.  1
2 NCC-LMS1-X3-C1 PDX 2
3 NCC-LMS2-C1            PDC   in preparation
4 Undifferentiated pleomorphic sarcoma (UPS) NCC-UPS1-C1 PDC   3
5 NCC-UPS1-X3-C1 PDX   4
6 NCC-UPS2-C1 PDC   5
7 NCC-UPS3-C1 PDC   in preparation
8 NCC-UPS4-C1 PDC   in preparation
9 Malignant peripheral nerve sheath tumor(MPNST)

NCC-MPNST1-C1

PDC   6
10 NCC-MPNST2-C1 PDC These cell line was established from tumors of MPNST of bone. 6
11 NCC-MPNST3-C1 PDC   6
12 NCC-MPNST3-X2-C1 PDX   6
13 NCC-MPNST4-C1 PDC   6
14 NCC-MPNST5-C1 PDC   6
15 Osteosarcoma

NCC-OS1-C1

PDC conventional osteosarcoma 7
16 NCC-ESOS1-C1 PDC extraskeletal osteosarcoma 8
17 Clear cell sarcoma NCC-CCS1B-C1 PDC EWSR1-ATF1 fusion gene 9
18 NCC-CCS1B-X2-C1 PDX EWSR1-ATF1 fusion gene 9
19 NCC-CCS1-X4-C1 PDX EWSR1-ATF1 fusion gene 9
20 CIC-DUX4 NCC-CDS1-X1-C1 PDX CIC-DUX4 fusion gene 10
21 NCC-CDS1-X3-C1 PDX CIC-DUX4 fusion gene. 10
22 NCC-CDS2-C1 PDC CIC-DUX4 fusion gene. 11
23 Rhabdomyosarcoma NCC-pRMS1-C1 PDC pleomorphic rhabdomyosarcoma 12
24 NCC-pRMS1-X4-C1 PDX pleomorphic rhabdomyosarcoma 12
25 NCC-ssRMS1-C1 PDC spindle-cell/sclerosing rhabdomyosarcoma 13
26 NCC-aRMS1-C1 PDC alveolar rhabdomyosarcoma in preparation
27 Synovial sarcoma NCC-SS1-C1 PDC SYT-SSX1 fusion gene 14
28 NCC-SS2-C1 PDC SYT-SSX2 fusion gene 15
29 NCC-SS3-C1 PDC SYT-SSX1 fusion gene 16
30 Dermatofibrosarcoma protuberans (DFSP) NCC-DFSP1-C1 PDC COL1A1(exon 33)-PDGFB(exon 2) fusion gene 17
31 NCC-DFSP2-C1 PDC COL1A1(exon 42)-PDGFB(exon 2) fusion gene 17
32 NCC-DFSP3-C1 PDC COL1A1(exon 25)-PDGFB(exon 2) fusion gene 18
33 Myxofibrosarcoma NCC-MFS1-C1 PDC   19
34 NCC-MFS2-C1 PDC   in preparation
35 Ewing's sarcoma NCC-ES1-C1 PDC EWSR1-FLI1 fusion gene 20
36 Chondrosarcoma NCC-dCS1-C1 PDC dedifferentiated chondrosarcoma 21
37 NCC-dCS2-C1 PDC dedifferentiated chondrosarcoma in preparation
38 Alveolar soft part sarcoma (ASPS) NCC-ASPS1-C1 PDC ASPL-TFE3 fusion gene submitted
39 Giant cell tumor of bone (GCT) NCC-GCTB1-C1 PDC giant cell tumor of bone. H3F3A mutation in preparation
40 NCC-GCTB2-C1 PDC giant cell tumor of bone. H3F3A mutation in preparation
41 NCC-GCTB3-C1 PDC giant cell tumor of bone. H3F3A mutation in preparation
42 NCC-TGCT1-C1 PDC Tenosynovial giant cell tumor. COL6A3-CSF1 fusion gene in preparation
43 Liposarcoma NCC-MLS1-C1 PDC Myxoid liposarcoma. FUS-CHOP fusion gene submitted
44 NCC-DDLS1-C1 PDC Dedifferentiated liposarcoma. MDM2 amplifiacation in preparation
45 NCC-DDLS2-C1 PDC Dedifferentiated liposarcoma. MDM2 amplifiacation in preparation
46 NCC-PLS1-C1 PDC Pleomorphic liposarcoma in preparation

References

  1. Sakumoto M, Takahashi M, Oyama R, Takai Y, Kito F, Shiozawa K, Qiao Z,Yoshida A, Endo M, Kawai A, Kondo T. stablishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma of the bone. Jpn J Clin Oncol. 2017 Oct 1;47(10):954-961. doi: 10.1093/jjco/hyx096. PMID: 28981730.[PubMed](external link)

  2.  Oyama R, Takahashi M, Kito F, Sakumoto M, Shiozawa K, Qiao Z, Yoshida A, Endo M, Kawai A, Kondo T. Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone. In Vitro Cell Dev Biol Anim. 2018 Jun;54(6):458-467. doi: 10.1007/s11626-018-0258-2. Epub 2018 May 29. PMID: 29845452.[PubMed](external link)
  3. Takai Y, Oyama R, Kito F, Sakumoto M, Shiozawa K, Qiao Z, Nakajima K, Takahashi M, Yoshida A, Setsu N,  Kobayashi E, Kawai A, Kondo T. Establishment and characterization of cell line of undifferentiated pleomorphic sarcoma.Tiss. Cult. Res. Commun. (2017) 36, 41-48. [J-Stage](external link)
  4. Kito F, Oyama R, Takahashi M, Shiozawa K, Sakumoto M, Yoshida A, Setsu N, Kobayashi E, Kawai A, Kondo T. Establishment and characterization of a patient-derived cancer model of undifferentiated pleomorphic sarcoma. Tiss. Cult. Res. Commun. (2018) 37, 1–13. [J-Stage](external link)
  5. Oyama R, Kito F, Sakumoto M, Shiozawa K, Toki S, Yoshida A, Kawai A, Kondo T. Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. In Vitro Cell Dev Biol Anim. 2018 Mar;54(3):257-263. doi:10.1007/s11626-018-0229-7. Epub 2018 Jan 22. PMID:29359268.[PubMed](external link)
  6. Oyama R, Kito F, Takahashi M, Hattori E, Noguchi R, Takai Y, Sakumoto M, Qiao Z, Toki S, Sugawara M, Tanzawa Y, Kobayashi E, Nakatani F, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors. Cancer Cell Int. 2020 Feb 19;20:58. doi: 10.1186/s12935-020-1128-z. PMID: 32099531; PMCID: PMC7031935.[PubMed](external link)

  7. Kito F, Oyama R, Sakumoto M, Takahashi M, Shiozawa K, Qiao Z, Sakamoto H,Hirose T, Setsu N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line. In Vitro Cell Dev Biol Anim. 2018 Aug;54(7):528-536. doi:10.1007/s11626-018-0274-2. Epub 2018 Jun 25. PMID: 29943355.[PumMed](external link)

  8. Kito F, Oyama R, Noguchi R, Hattori E, Sakumoto M, Endo M, Kobayashi E, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1. Hum Cell. 2020 Jan;33(1):283-290. doi: 10.1007/s13577-019-00291-z. Epub 2019 Oct 17. PMID:31625124.In Vitro Cell Dev Biol Anim (2018) 54,770-778. [PubMed](external link)

  9. Sakumoto M, Oyama R, Takahashi M, Takai Y, Kito F, Shiozawa K, Qiao Z, Endo M, Yoshida A, Kawai A, Kondo T. Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines. In Vitro Cell Dev Biol Anim. 2018 Feb;54(2):163-176. doi: 10.1007/s11626-017-0207-5. Epub 2017 Dec 1. PMID: 29197033.[PubMed](external link)

  10.  Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F, Shiozawa K, Qiao Z, Arai Y, Shibata T, Araki Y, Endo M, Kawai A, Kondo T. Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. Sci Rep. 2017 Jul 5;7(1):4712. doi: 10.1038/s41598-017-04967-0. PMID: 28680140; PMCID:PMC5498486. [PumMed](external link)
  11. Yoshimatsu Y, Noguchi R, Tsuchiya R, Kito F, Sei A, Sugaya J, Nakagawa M,Yoshida A, Iwata S, Kawai A, Kondo T. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 2020 Apr;33(2):427-436. doi: 10.1007/s13577-019-00312-x. Epub 2020 Jan 2. PMID:31898195.Human Cell (2019). [PubMed](external link)

  12. Oyama R, Kito F, Sakumoto M, Shiozawa K, Toki S, Yoshida A, Kawai A,  Kondo T. Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. Tiss. Cult. Res. Commun. (2018) 37,147-158.  [J-Stage](external link)
  13. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, Iwata S, Sugiyama M,Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-ssRMS1-C1: a novel patient-derived spindle-cell/sclerosing rhabdomyosarcoma cell line. Hum Cell. 2020 Apr 16. doi: 10.1007/s13577-020-00359-1. Epub ahead of print. PMID: 32300959.[PubMed](external link)

  14. Kito F, Oyama R, Takai Y, Sakumoto M, Shiozawa K, Qiao Z, Uehara T, Yoshida A, Kawai A, Kondo T. Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. Hum Cell. 2018 Apr;31(2):167-174. doi:10.1007/s13577-018-0199-9. Epub 2018 Feb 15. PMID: 29450702.[PubMed](external link)

  15. Oyama R, Kito F, Sakumoto M, Shiozawa K, Toki S, Endo M, Yoshida A, Kawai A, Kondo T. Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1. In Vitro Cell Dev Biol Anim. 2018 May;54(5):392-399. doi: 10.1007/s11626-018-0237-7. Epub 2018 Apr 6. PMID:29626278.[PubMed](external link)

  16. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, Iwata S, Yoshida A,Kawai A, Kondo T. Establishment and Characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2020 Apr 9. doi:10.1007/s13577-020-00354-6. Epub ahead of print. PMID: 32274656.[PubMed](external link)

  17. Oyama R, Kito F, Qiao Z, Sakumoto M, Shiozawa K, Toki S, Yoshida A, Kawai A, Kondo T. Establishment of novel atient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1. In Vitro Cell Dev Biol Anim. 2019 Jan;55(1):62-73. doi: 10.1007/s11626-018-0305-z. Epub 2018 Nov 8. PMID: 30411273.[PubMed](external link)

  18. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Nakagawa M, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2020 Apr 30. doi:10.1007/s13577-020-00365-3. Epub ahead of print. PMID: 32356243.[PubMed](external link)

  19. Kito F, Oyama R, Sakumoto M, Shiozawa K, Qiao Z, Toki S, Yoshida A, Kawai A, Kondo T. Establishment and Characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019 Apr;32(2):214-222.doi: 10.1007/s13577-018-00233-1. Epub 2019 Feb 8. PMID: 30737712.[PubMed](external link)

  20. Oyama R, Kito F, Qiao Z, Sakumoto M, Noguchi R, Takahashi M, Toki S, Tanzawa Y, Yoshida A, Kawai A, Kondo T. Establishment of a novel patient-derived Ewing's sarcoma cell line, NCC-ES1-C1. In Vitro Cell Dev Biol Anim. 2018 Dec;54(10):770-778. doi: 10.1007/s11626-018-0302-2. Epub 2018 Oct 15. PMID:30324244. [PubMed](external link)

  21. Oyama R, Kito F, Takahashi M, Sakumoto M, Shiozawa K, Qiao Z, Noguchi R,Kubo T, Toki S, Nakatani F, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1. Hum Cell. 2019 Apr;32(2):202-213. doi: 10.1007/s13577-018-0232-2. Epub 2019 Feb 8. PMID: 30737713.[PubMed](external link)